Skip to main content
. 2022 May 18;6:e2100522. doi: 10.1200/PO.21.00522

FIG A1.

FIG A1.

Study schema. The schematic describes the study design and key eligibility criteria. *Treatment beyond progression permitted at investigator discretion. AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; NGS, next-generation sequencing; NSCLC, non–small-cell lung cancer; TKI, tyrosine kinase inhibitor.